isoxazoles has been researched along with Sclerosis, Systemic in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantatore, FP; Corrado, A; Costantino, E; Foschino Barbaro, MP; Neve, A; Palladino, GP | 1 |
| Martins-Filho, OA; Mota, LM; Oliveira, AC; Santos-Neto, LL; Simões, M; Tauil, PL | 1 |
| Ohashi, T; Yamamoto, T | 1 |
| Coghlan, G; Kabunga, P | 1 |
| Becker, H; Domschke, W; Gaubitz, M; Mohr, M; Sunderkoetter, C; Willeke, P | 1 |
| Champion, HC; Girgis, RE; Hassoun, PM; Hummers, LK; Mathai, SC; Wigley, FM; Zaiman, A | 1 |
| Bellamy, CO; Dhaun, N; Kluth, DC; MacIntyre, IM | 1 |
| Derk, CT; Shetty, N | 1 |
| Akhmetshina, A; Allanore, Y; Avouac, J; Beyer, C; Dees, C; Distler, JH; Distler, O; Horn, A; Maurer, B; Palumbo, K; Sadowski, A; Schett, G; Schneider, H; Shiozawa, S; Tomcik, M; Zerr, P | 1 |
| Hintz, E; Klein, R; Staehler, G | 1 |
| Celermajer, DS; Corte, TJ; Don, GW; Joseph, F | 1 |
| Brizzolara, R; Cutolo, M; Ferrone, C; Montagna, P; Parodio, A; Seriolo, B; Soldano, S; Sulli, A; Villaggio, B | 1 |
| Gordeev, AV; Mutovina, ZIu; Nasankaeva, EK | 1 |
| Caruso, A; Ferri, C; Giuggioli, D; Sebastiani, M; Vesprini, E | 1 |
2 review(s) available for isoxazoles and Sclerosis, Systemic
| Article | Year |
|---|---|
Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome | 2008 |
Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelins; Familial Primary Pulmonary Hypertension; Fibrosis; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome | 2011 |
12 other study(ies) available for isoxazoles and Sclerosis, Systemic
| Article | Year |
|---|---|
Effect of endothelin inhibition on lung fibroblasts on patients with systemic sclerosis.
Topics: Actins; Adult; Aged; Cell Differentiation; Cell Survival; Collagen Type I; Endothelin Receptor Antagonists; Endothelins; Female; Fibroblasts; Fibronectins; Humans; Isoxazoles; Lung; Male; Middle Aged; Muscle, Smooth; Myofibroblasts; Scleroderma, Systemic; Thiophenes; Vascular Endothelial Growth Factor A | 2013 |
Seroconversion in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, who were inadvertently revaccinated against yellow fever.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Child; Contraindications; Female; Humans; Immunity, Innate; Immunization, Secondary; Immunologic Factors; Immunosuppressive Agents; Infliximab; Isoxazoles; Leflunomide; Lupus Erythematosus, Systemic; Middle Aged; Retrospective Studies; Rheumatic Diseases; Rituximab; Scleroderma, Systemic; Yellow Fever; Yellow Fever Vaccine; Young Adult | 2015 |
Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
Topics: Animals; Bleomycin; Cell Count; Chemokine CCL3; Collagen Type I; Connective Tissue Growth Factor; Disease Models, Animal; Female; Fibrosis; Hydroxyproline; Interferon-gamma; Isoxazoles; Lung; Mast Cells; Mice; Propionates; Receptors, Lysophosphatidic Acid; RNA, Messenger; Scleroderma, Systemic; Skin; Smad2 Protein; Smad3 Protein; Transforming Growth Factor beta1 | 2015 |
[Leg ulcer in mixed connective tissue disease. Resolution during sitaxsentan therapy].
Topics: Adult; Antihypertensive Agents; Female; Humans; Isoxazoles; Leg Ulcer; Raynaud Disease; Scleroderma, Systemic; Thiophenes; Treatment Outcome | 2009 |
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Topics: Bosentan; Cohort Studies; Comorbidity; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Lung Diseases, Interstitial; Male; Maryland; Middle Aged; Piperazines; Prognosis; Proportional Hazards Models; Purines; Receptors, Endothelin; Scleroderma, Diffuse; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Vasodilator Agents | 2009 |
Endothelin receptor antagonism and renin inhibition as treatment options for scleroderma kidney.
Topics: Amides; Antihypertensive Agents; Atrophy; Biomarkers; Biopsy; Endothelin Receptor Antagonists; Female; Fibrosis; Fumarates; Humans; Hypertension, Renal; Isoxazoles; Kidney; Middle Aged; Proteinuria; Pulmonary Fibrosis; Renal Insufficiency, Chronic; Renin; Scleroderma, Systemic; Thiophenes; Treatment Outcome | 2009 |
Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis.
Topics: Animals; Benzophenones; Bleomycin; Cells, Cultured; Collagen; Disease Models, Animal; Female; Fibroblasts; Fibrosis; Gene Expression; Humans; Isoxazoles; JNK Mitogen-Activated Protein Kinases; Male; Mice; Proto-Oncogene Proteins c-fos; RNA, Small Interfering; Scleroderma, Systemic; Signal Transduction; Transcription Factor AP-1; Transfection; Transforming Growth Factor beta; Up-Regulation | 2012 |
Exacerbation of AIH in a patient with an AIH/systemic sclerosis overlap syndrome and pulmonary arterial hypertension treated with the endothelin-1 receptor antagonist sitaxentan.
Topics: Autoantibodies; Autoantigens; Disease Progression; Endothelin A Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Hepatitis, Autoimmune; Humans; Hypertension, Pulmonary; Isoxazoles; Middle Aged; Scleroderma, Systemic; Thiophenes; Treatment Outcome | 2012 |
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Liver Function Tests; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Safety-Based Drug Withdrawals; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2012 |
Endothelin receptor antagonists: effects on extracellular matrix synthesis in primary cultures of skin fibroblasts from systemic sclerosis patients.
Topics: Aged; Bosentan; Cells, Cultured; Collagen Type I; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Extracellular Matrix Proteins; Female; Fibrillin-1; Fibrillins; Fibroblasts; Fibronectins; Fibrosis; Humans; Isoxazoles; Microfilament Proteins; Middle Aged; Primary Cell Culture; Scleroderma, Systemic; Sulfonamides; Thiophenes | 2012 |
[Effective treatment of systemic sclerosis with leflunomide].
Topics: Aged; Female; Humans; Isoxazoles; Leflunomide; Scleroderma, Systemic; Treatment Outcome | 2005 |
Successful treatment with leflunomide of arthritis in systemic sclerosis patients.
Topics: Adult; Antirheumatic Agents; Arthritis; Female; Humans; Isoxazoles; Leflunomide; Middle Aged; Scleroderma, Systemic | 2006 |